Online Exclusives

2026 Medical Device Industry M&A Roundup (Updated 6/16)

MPO's catalogue of the medtech market's M&A transactions, updated throughout the year.

Author Image

By: Sam Brusco

Associate Editor

Merger and acquisition (M&A) transactions remain prevalent in the medical device manufacturing industry in many forms—larger organizations making bolt-on acquisitions of smaller, innovative companies and/or businesses, mergers of equals, private equity deals, and medical product outsourcing providers grabbing specialty businesses to round out their offerings on the journey to full service.

To help our readers stay up to date about the medical device market’s evolution, MPO will catalog these M&A transactions throughout the year. We hope this will be a helpful resource!

Cretex Medical—Holland Molds

Cretex Medical has acquired select assets and capabilities of Holland Molds Inc. in Wadena, Minn. Neither company disclosed the deal’s terms. Known for its excellent quality and dedication to customer satisfaction, Holland provides sophisticated tooling for plastic injection molding.
Date of Announcement: June 16, 2026
Value: Not disclosed
More info

Spectrum Vascular—Piccolo Medical

Piccolo’s real-time catheter guidance leverages proprietary blood flow sensing technology to guide catheter tip placement, removing the need for confirmatory chest X-rays.
Date of Announcement: June 11, 2026
Value: Not disclosed
More info

Novanta—Riverpoint Medical

Riverpoint Medical is a developer, designer, and manufacturer of advanced surgical fibers and related technologies, offering private-label minimally invasive surgical consumables and instruments for markets including sports medicine, trauma, and cardiovascular surgery.
Date of Announcement: June 9, 2026
Value: $1.2 billion upfront, $250 milestone payment in Q2 2027
More info

Cordica Medical—RapidWerks Micro Molding

The deal adds dedicated, automated micro molding for mass production to Cordica’s integrated design and manufacturing platform. This includes equipment designed for repeatable and robust shot-size accuracy and for producing parts that consistently weigh a fraction of a gram.
Date of Announcement: June 4, 2026
Value: Not disclosed
More info

Olympus—BioProtect

BioProtect develops implant technologies to improve prostate cancer care and boost patients’ quality of life. Its flagship Balloon Spacer system provides consistent spacing between the prostate and other critical structures to protect healthy tissues during prostate cancer radiation therapies.
Date of Announcement: May 26, 2026
Value: $270 million
More info

Endologix—Surmodics

Endologix acquired Surmodics’ Pounce system, an FDA-cleared mechanical thrombectomy system for non-surgical removal of thrombi and emboli from peripheral arteries.
Date of Announcement: May 19, 2026
Value: Not disclosed
More info

Boston Scientific—MiRus

Boston Scientific invested for a 34% stake in MiRus, a company that developing and commercializing biomaterials, implants, and procedural solutions to treat cardiovascular and orthopedic diseases, including the Siegel balloon expandable TAVR.
Date of Announcement: May 18, 2026
Value: $1.5 billion
More info

Artivion—Endospan

Artivion gains the Nexus aortic arch system, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for open surgical repair.
Date of Announcement: May 18, 2026
Value: $175 million, potential for up to further $200 million contingent on commercial performance
More info

Roche—PathAI

PathAI is a U.S.-based company that specializes in digital pathology and AI-powered tech for pathology labs and the biopharma industry.
Date of Announcement: May 6, 2026
Value: $750 million upfront, further milestone payments up to $300 million
More info

Johnson & Johnson—Atraverse Medical

Atraverse’s Hotwire transseptal access system is an FDA-cleared RF guidewire and generator system used for more confidence and control when accessing the left atrium.
Date of Announcement: April 24, 2026
Value: Not disclosed
More info

Stereotaxis—Robocath

Merging Stereotaxis’ magnetic navigation tech and Robocath’s mechanical robotic system creates a differentiated fully robotic solution for endovascular surgery.
Date of Announcement: April 15, 2026
Value: $20 million upfront, contingent payments of up to $25 million
More info

Stryker—Amplitude Vascular Systems

Amplitude Vascular Systems Inc. (AVS) is a privately held medical technology firm developing a next-generation intravascular lithotripsy (IVL) platform for treating calcified peripheral arterial disease. 
Date of Announcement: April 13, 2026
Value: Not disclosed
More info

Windjammer Capital—PrecisionX Group

The partnership marks a significant milestone in PrecisionX’s growth trajectory and strengthens the company’s ability to serve customers across its core end markets.
Date of Announcement: April 1, 2026
Value: Not disclosed
More info

embecta—Owen Mumford

Owen Mumford’s products include a quickly growing pharmaceutical services portfolio built on historic autoinjector success with established pharma companies.
Date of Announcement: March 19, 2026
Value: £150 million ($199.4 million)
More info

Medtronic—Scientia Vascular

Medtronic announced its intention to acquire Scientia Vascular, a company developing technology designed to improve navigability through complex neurovascular anatomy. 
Date of Announcement: March 10, 2026 (completed June 12, 2026)
Value: $550 million, with potential undisclosed earn-out and milestone payments post-acquisition.
More info

Plastic Ingenuity—Spezi-Pack

Plastic Ingenuity is expanding its operations in Europe by acquiring German thermoforming provider Spezi-Pack.
Date of Announcement: March 9, 2026
Value: Not disclosed
More info

MGS-Knudsen Plast A/S

MGS announced its acquisition of Denmark-based injection molder Knudsen Plast A/S, an organization with more than four decades of healthcare manufacturing experience. 
Date of Announcement: February 23, 2026
Value: Not disclosed
More info

Danaher—Masimo

Masimo develops patient monitoring devices, non-invasive sensors, and related software platforms used in hospital and home settings. It will become a become a standalone, autonomously operating business unit and brand in Danaher’s Diagnostics segment.
Date of Announcement: February 17, 2026 (closed June 10, 2026)
Value: $180 per share in cash ($9.9 billion)
More info

Vygon—Avia Vascular’s Stiletto

Vygon has acquired Stiletto, a new generation of extended‑dwell catheters integrating SlipStream technology, from Salt Lake City-based Avia Vascular.
Date of Announcement: Feb. 11, 2026
Value: Not disclosed
More info

Medtronic—CathWorks

Privately-held CathWorks bolsters Medtronic’s catheterization technological prowess. The medical device giant has held a minority stake in the Israeli diagnostics firm since 2018.
Date of Announcement: Feb. 3, 2026
Value: Up to $585 million, potential earn-out payments once deal is complete
More info

Invio Automation—Calvary Robotics Inc.

Together, the combined business will be able to better serve the complex automation and high-precision system needs of customers from concept and simulation through build, deployment, and continuous optimization.
Date of Announcement: Feb. 2, 2026
Value: Not disclosed
More info

Symmetry Laser—ArcRev

ArcRev adds complementary laser cutting tech, technical talent, and disciplined operating practices aligned with Symmetry’s manufacturing approach.
Date of Announcement: January 28, 2026
Value: Not disclosed
More info

Resonetics—Resolution Medical

Resolution provides of integrated design and manufacturing solutions for complex medical devices—it adds complementary capabilities of neuromodulation, structural heart, and interventional cardiology.
Date of Announcement: January 27, 2026
Value: Not disclosed
More info

BioStem Technologies—BioTissue Holdings’ Surgical and Wound Care Business

The deal expands access to major GPO networks, strengthening BioStem’s position across hospital settings.
Date of Announcement: January 21, 2026
Value: $15 million upfront cash payment, potential for additional regulatory milestone payment of up to $10 million for 510(k) clearance for a new product, potential commercial royalty milestone payments of up to $15 million
More info

Boston Scientific—Penumbra

Penumbra provides mechanical thrombectomy products that are used in peripheral vascular procedures to remove blood clots.
Date of Announcement: January 15, 2026
Value: $374 per share, $14.5 billion enterprise value
More info

Boston Scientific—Valencia Technologies

Valencia’s eCoin system is an implantable tibial nerve stimulation device to treat urinary urge incontinence, a common symptom of overactive bladder.
Date of Announcement: January 12, 2026
Value: Not disclosed
More info

Edwards—JenaValve (Terminated)

The U.S. District Court for the District of Columbia granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction to block the company’s proposed acquisition of JenaValve.
Date of Announcement: January 9, 2026
More info

Haemonetics—Vivasure

Vivasure’s PerQseal Elite system uses a proprietary bioabsorbable patch to seal large-bore (up to 26F) arteriotomies and venotomies from inside the vessel.
Date of Announcement: January 9, 2026
Value: Up to €185 million
More info

NAMSA—Labcorp

NAMSA will assume the U.S. portfolio of services of Labcorp’s Early Development medical device business, including biocompatibility testing, microbiological testing, analytical testing, and preclinical research.
Date of Announcement: January 8, 2026
Value: Not disclosed
More info

Arterex—Synecco

Synecco is based in Ireland and boasts expertise in the structural heart space, with the addition of injection molding and assembly capabilities.
Date of Announcement: January 6, 2026
Value: Not disclosed
More info

Alcon—STAAR Surgical (Terminated)

STAAR did not receive the necessary stockholder votes to approve the merger agreement with Alcon at its Special Meeting of Stockholders, resulting in termination.
Date of Announcement: January 6, 2026
More info

Resonetics—Med-Ally

This deal includes manufacturing assets, process know-how, and intellectual property related to implantable and external pulse generators as well as leads manufacturing and assembly.
Date of Announcement: January 6, 2026
Value: Not disclosed
More info

W.L. Gore & Associates (Gore)—Conformal Medical

Conformal Medical develops the investigational CLAAS AcuFORM system, a next-gen left atrial appendage occlusion (LAAO) device.
Date of Announcement: January 5, 2026
Value: Not disclosed
More info

Year-by-Year

2025 Medical Device Companies M&A Roundup
2024 Medical Device Manufacturing M&A Roundup

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters